Paediatric cerebral sinus vein thrombosis

Summary

The etiology and pathophysiology of cerebral sinus venous thrombosis (CSVT) in the paediatric population is still poorly understood, and the role of thrombophilic risk factors remains to be elucidated. In our multi-center case-controlled study we studied 46 patients with CSVT diagnosed from April 1996 to December 2003, consecutively referred for thrombophilia work-up. The results of thrombophilia screen were compared to 112 healthy paediatric controls. Anticoagulant therapy was applied according to treating physicians’ decisions, and all cases were prospectively followed for a median of 4.1 years. Of 46 children, 8 had CSVT diagnosed in the neonatal period and therefore were analyzed separately. The prevalence of single thrombophilia markers and combinations of thrombophilic risk factors were similar among cases and controls. Among children with CSVT co-morbid systemic illness was present in most patients at diagnosis. Seven out of 8 children with idiopathic CSVT had thrombophilic risk factors as compared to 31/38 patients with co-morbid conditions. Anticoagulation was initiated in most patients, 11/46 patients continued therapy for a total of one year or more post event. Neither clinical presentation nor initial treatment decisions were affected by presence of thrombophilic risk factors in our study group. Thrombophilia prevalence was not increased in children with CSVT as compared to controls, however thrombophilia was more frequent among children with idiopathic CSVT. Thus, those selected patients would benefit most from thrombophilia work-up, required for long-term therapy considerations.

Keywords

Cerebral sinus vein thrombosis - thrombophilia - paediatric

• References

• 1 DeVeber G, Andrew M, Adams C. et al. Cerebral sinovenous thrombosis in children. N Eng J Med 2001; 345: 417-23.
• 2 Visudtibhan A, Visudhiphan B, Chiemchanya S. Cavernous sinus thrombophlebitis in children. Pediatr Neurol 2001; 24: 238-43.
• 3 Lee BC, Voorhies TM, Ehrlich ME. et al. Digital intravenous cerebral angiography in neonates. Am J Neroradiol 1984; 05: 281-6.
• 4 Baram TZ, Butler IJ, Nelson MD. et al. Transverse sinus thrombosis in newborns: clinical and magnetic resonance imaging findings. Ann Neurol 1998; 24: 792-4.
• 5 Barron TF, Goosnard DA, Zimmerman RA. et al. Cerebral venous thrombosis in neonates and children. Pediatr Neurol 1992; 08: 112-16.
• 6 Heller C, Heinecke A, Junker R. et al. Cerebral venous thrombosis in children – a multifactorial study. Circulation 2003; 108: 1362-7.
• 7 Dalback B. New molecular insights of thrombophilia: resistance to activated protein C caused by Arg506 to Gln. Mutation in factor V as pathogenetic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
• 8 Frosst P, Bloom HJ, Milos R. et al. A candidate genetic risk factor for vascular disease: a acommon mutation in methylene-tetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
• 9 Poort SR, Rosendal FR, Rewifman PH. et al. A common genetic variation in the 3’ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 10 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism. Arteriscler Thromb Vasc Biol 1999; 19: 511-18.
• 11 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in paediatric patients. Thromb Haemost 1995; 74: 415-25.
• 12 Andrew M, David M, Adams M. et al. Venous thromboembolic (VTE) complications in children: first analyses of the Canadian registry of VTE. Blood 1994; 83: 1252-7.
• 13 Heleen Van-Omen C, Heijboer B, Buller HR. et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Ped 2001; 139: 676-81.
• 14 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Paedritics 1995; 96: 939-43.
• 15 Nowak-Gottl U, Von-Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal ed 1997; 76: F163-F167.
• 16 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. New Eng J Med 2001; 344: 1222-31.
• 17 Heller C, Schobess R, Kurnik K. et al. Abdominal thrombosis in neonates and infants: role of prothrombotic risk factors – a multicenter case-control study. Br J Hematol 2000; 111: 534-9.
• 18 Uttenreuther-Fischer MM, Vetter B, Hellmann C. et al. Paediatric thromboembolism; the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Ped 1996; 156: 227-81.
• 19 Bonduel M, Sciuccati G, Hepner M. et al. Prethrombotic disorders in children with ischenic stroke and sinovenous thrombosis. Arch Neurol 1999; 56: 967-71.
• 20 Martinelli I, Sacchi E, Landi G. et al. High risk of cerebral-vein thrombosis in carriers of prothrombin-gene mutation and in users of oral contraceptives. N Eng J Med 1998; 338: 1793-7.
• 21 Zuber M, Toulon P, Marnet L. et al. Factor V Leiden mutation in cerebral sinus venous thrombosis. Stroke 1996; 27: 1721-3.
• 22 Deschiiens MA, Conrad J, Horellou MH. et al. Coagulation studies, factor V Leiden and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996; 27: 1724-30.
• 23 Carvalho KS, Bdensteiner JB, Connoly PJ. et al. Cerebral venous thrombosis in children. J Child Neurol 2001; 16: 574-80.
• 24 Kenet G, Sadetzki S, Murad H. et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
• 25 Cantu C, Barinagarremeteria F. Cerebral venous thrombosis associated with pregnancy and puerperium: review of 67 cases. Stroke 1993; 24: 1880-4.
• 26 Hicky WF, Garnick MB, Henderson IC. et al. Primary cerebral venous thrombosis in patients with cancer-a rarely diagnosed paraneoplastic syndrom: report of three cases and review of the literature. Am J Med 1982; 73: 740-50.
• 27 Uziel Y, Laxer RM, Blaser S. et al. Cerebral vein thrombosis in childhood systemic lupus erythematosus. J Pediatr 1995; 126: 722-77.
• 28 Einhaupl KM, Villringer A, Meister W. et al. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600.
• 29 DeBruijn SF, Stam J. Randomised, placebocontrolled trial of anticoagulant treatment with low-molecular weight heparin for cerebral sinus thrombosis. Stroke 1999; 30: 484-8.
• 30 Stam J, deBruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis. Stroke 2003; 34: 1054-5.
• 31 Ferro J, Canhao P, Stam J. et al. Prognosis of cerebral vein and dural sinus thrombosis. Stroke 2004; 35: 664.